Basma M. T. Abdoullateef

Basma M. T. Abdoullateef

Auto-generated profile, based on publicly available information

Basma M. T. Abdoullateef

Department of Chemistry, School of Sciences and Engineering, The American University in Cairo, New Cairo, AUC Avenue, SSE # 1184, P.O. Box 74, Cairo 11835, Egypt

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2024 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
BABasma M. T. Abdoullateef
Basma M. T. Abdoullateef
SASaif El-Din Al-Mofty
Saif El-Din Al-Mofty
Hassan AzzazyHassan Azzazy
Hassan Azzazy
General anaesthetics are routinely used to sedate patients during prolonged surgeries and administered via intravenous injection and/or inhalation. All anaesthetics have short half-lives, hence the need for their continuous administration. This causes several side effects such as pain, vomiting, nausea, bradycardia, and on rare occasions death post-administration. Several clinical trials studied the synergetic effect of a combination of anaesthetic drugs to reduce the drug load. Another solution is to encapsulate anaesthetics in nanoparticles to reduce their dose and side effects as well as achieve their sustained release manner. Different types of nanoparticles were developed as carriers of intravenous and intrathecal anaesthetics generating platforms which facilitate drug transport across the blood–brain barrier (BBB). Nanocarriers encapsulating common anaesthetic drugs such as propofol, etomidate, and ketamine were developed and characterized in terms of size, stability, onset and duration of loss of right reflex, and tolerance to pain in small animal models. The review discusses the types of nanocarriers used to reduce the side effects of the anaesthetic drugs while prolonging the sedation time. More rigorous studies are still required to evaluate the nanocarrier formulations regarding their ability to deliver anaesthetic drugs across the BBB, safety, and finally applicability in clinical settings.